Complementary and alternative medicine usage for behavioral health indications

Primary Care - Clinics in Office Practice

Volumn 37, Issue 2, 2010, Pages 213-236

  Larzelere, Michele M ^a   Campbell, James S ^a   Robertson, Marta ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anxiety; Attention deficit hyperactivity disorder (ADHD); Complementary and alternative medicine; Depression; Dietary supplements; Insomnia

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; CROCUS SATIVUS EXTRACT; DIAZEPAM; DIGOXIN; FLUOXETINE; FOLIC ACID; FOLINIC ACID; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; INOSITOL; KAVA; LEVACECARNINE; MELATONIN; NEFAZODONE; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PASSIFLORA INCARNATA EXTRACT; PLACEBO; PRASTERONE; PYCNOGENOL; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; TRYPTOPHAN; UNINDEXED DRUG; VALERIAN; WARFARIN; ZINC SULFATE;

ACUPRESSURE; AGITATION; ALTERNATIVE MEDICINE; ANXIETY; ANXIETY DISORDER; ATAXIA; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; CHIROPRACTIC; CLINICAL TRIAL; CONFUSION; DECREASED APPETITE; DEPRESSION; DIET SUPPLEMENTATION; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERICUM PERFORATUM; HYPOGLYCEMIA; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MAJOR DEPRESSION; MANIPULATIVE MEDICINE; MASSAGE; MENTAL DISEASE; NAUSEA; NERVOUSNESS; PARESTHESIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TASTE AVERSION; XEROSTOMIA;

ANXIETY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLEMENTARY THERAPIES; DEPRESSION; HUMANS; MENTAL DISORDERS; PHYTOTHERAPY; SLEEP DISORDERS;

EID: 77952906723     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.02.002     Document Type: Review

References (128)

1. Kessler R.C., Soukoup J., Davis R.B., et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001, 158:289-294.
2. Barnes PM, Bloom B, Nahin R. CDC National Health Statistics Report #12. Complementary and alternative medicine use among adults and children: United States, 2007. Available at: Accessed March 16, 2010. http://www.nccam.nih.gov/news/2008/nhsr12.pdf.
3. NIH state-of-the-science conference statement on multivitamin/mineral supplements and chronic disease prevention. Ann Intern Med 2006, 145:364-371.
4. National Center for Complementary and Alternative Medicine (NCCAM) The use of complementary and alternative medicine in the United States. Based upon National Center for Health Statistics National Health Interview Survey 2007 Available at:, Accessed June 15, 2009. http://nccam.nih.gov/news/camsurvey_fs1.htm.
5. Jackson J.L., Passamonti M., Kroenke K. Outcome and impact of mental disorders in primary care at 5 years. Psychosom Med 2007, 69:270-276.
6. Wu P., Fuller C., Liu X.H., et al. Use of complementary and alternative medicine among women with depression: results of a national survey. Psychiatr Serv 2007, 58(3):349-356.
7. Muller W., Rolli M., Schafer U. Effects of hypericum extract (Li 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997, 30(2):102-107.
8. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; 4. Art No:CD000448.
9. Nierenberg A.A., Lund H.G., Mischoulon D. St. John's wort: a critical evaluation of the evidence for antidepressant effects. Natural medications for psychiatric disorders 2008, 27-38. Lippincott Williams, Wilkins, Philadelphia. 2nd edition. D. Mischoulon, J.F. Rosenbaum (Eds.).
10. Shelton R.C., Keller M.B., Gelenberg A., et al. Effectiveness of St. John's wort in major depression. A randomized controlled trial. JAMA 2001, 285:1978-1986.
11. Hypericum Depression Trial Study Group Effect of Hypericum perforatum (St John's wort) in major depressive disorder. A randomized controlled trial. JAMA 2002, 287:1807-1814.
12. Schrader E. Equivalence of St. John's wort extract (Ze117) and fluoxetine: a randomized controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000, 15(2):61-68.
13. Natural Medicines Comprehensive Database Available at:, Accessed June 15, 2009. http://www.naturaldatabase.com.
14. Woelk H,. Burkhard G, Gruenwald J. Evaluation of the benefits and risks of the Hypericum extract LI160 based on a drug monitoring study with 3250 patients. Nervenheilkunde 1993;12:308-13. Available at: Accessed February 5, 2009. http://www.schattauer.de/en/magazine/subject-areas/journals-a-z/nervenheilkunde.html.
15. Di Carlo G., Borrelli F., Ernst E., et al. St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci 2001, 22:292-297.
16. Hibbeln J.R. Fish consumption and major depression. Lancet 1998, 351:1213.
17. Tanskanen A., Hibbeln J.R., Hintikka J., et al. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry 2001, 58:512-513.
18. Stoll A.L. Omega-3 fatty acids in mood disorders: a review of neurobiologic and clinical actions. Natural medications for psychiatric disorders 2008, 39-67. Lippincott Williams, Wilkins, Philadelphia. 2nd edition. D. Mischoulon, J.F. Rosenbaum (Eds.).
19. Peet M., Horrobin D.F. A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002, 59:913-919.
20. Nemets B., Stahl Z., Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002, 159:477-479.
21. Su K.P., Huang S.Y., Chiu C.C., et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003, 13:267-271.
22. Nemets H., Nemets B., Apter A., et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006, 163:1098-1100.
23. Osher Y., Belmaker R.H. Omega-3 fatty acids in depression: a review of three studies. CNS Neurosci Ther 2009, 15(2):128-133.
24. Alpert J.E., Papakostas G.I., Mischoulon D. One-carbon metabolism and the treatment of depression: roles of S-adenosyl-L-methionine and folate. Natural medications for psychiatric disorders 2008, 68-83. Lippincott Williams, Wilkins, Philadelphia. 2nd edition. D. Mischoulon, J.F. Rosenbaum (Eds.).
25. Coppen A., Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000, 60:121-130.
26. Taylor M.J., Carney S.M., Goodwin G.M., et al. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol 2004, 18:251-256.
27. Alpert J.E., Mischoulon D., Rubenstein G.E., et al. Folinic acid (leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002, 14:33-38.
28. Bottiglieri T., Godfrey P., Flynn T., et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatr 1990, 53:1096-1098.
29. Hardy M.L., Coulter I., Morton S.C., et al. S-Adenosyl-methionine (ademethionine) for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ) 2003, 64:1-3.
30. Bressa G.M. S-Adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand 1994, 154(Suppl):7-14.
31. Mischoulon D., Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002, 76(5 Suppl):1158s-1161s.
32. Spillman M., Fava M. S-Adenosyl-methionine (ademethionine) in psychiatric disorders. CNS Drugs 1996, 6:416-425.
33. Chiaie R.D., Pancheri P., Scapicchio S. Efficacy and tolerability of oral and intramuscular S-adenosyl-l-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002, 76(Suppl):11172S-11176S.
34. Alpert J.E., Papakostas G., Mischoulon D., et al. S-Adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004, 24(6):661-664.
35. Alvarez E., Udina C., Guillamat R. Shortening of latency period in depressed patients treated with SAMe and other antidepressant drugs. Cell Biol Rev 1987, S1:103-110.
36. Berlanga C., Ortega-Soto H.A., Ontiveras M., et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992, 44:257-262.
37. Barkai A., Dunner D.L., Gross H.A., et al. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry 1978, 13:65-72.
38. Levine J., Barak Y., Gonsalves M., et al. Double-blind controlled trial of inositol treatment of depression. Am J Psychiatry 1995, 152:792-794.
39. Levine J., Mischory A., Susnosky S., et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry 1999, 45:270-273.
40. Taylor M.J., Wilder H., Bhagwagar Z., et al. Inositol for depressive disorders. Cochrane Database Syst Rev 2004, 1. CD004049.
41. Akhondzadeh S., Tahmacebi-Pour N., Noorbala A.A., et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res 2005, 19:148-151.
42. Moshiri E., Basti A.A., Noorbala A.A., et al. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine 2006, 13(9-10):607-611.
43. Basti A.A., Moshiri E., Noorbala A., et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:439-442.
44. Noorbala A.A., Akhondzadeh S., Tahmacebi-Pour N., et al. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol 2005, 97:281-284.
45. Akhondzadeh S., Fallah-Pour H., Afkham K., et al. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med 2004, 4:12.
46. Davidson J.R.T., Connor K.M. St. John's wort in generalized anxiety disorder: three case reports. J Clin Psychopharmacol 2001, 21:635-636.
47. Kobak K.A., Taylor L., Futterer R., et al. John's wort in generalized anxiety: three more case reports. J Clin Psychopharmacol 2003, 23:531-532.
48. Sarris J., Kavanagh D.J., Deed G., et al. St. John's wort and kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum Psychopharmacol 2009, 24:41-48.
49. Taylor L.H., Kobak K.A. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000, 61:575-578.
50. Kobak K.A., Taylor L.V., Bystritsky A., et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005, 20:299-304.
51. Kobak K.A., Taylor L.V., Warner G., et al. St John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005, 25:51-58.
52. Cropley M., Cave Z., Ellis J., et al. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res 2002, 16:23-27.
53. Kennedy D.O., Little W., Haskell C.F., et al. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res 2006, 20(2):96-102.
54. Andreatini R., Sartori V.A., Seabra M.L., et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002, 16:650-654.
55. Houghton P.J. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 1999, 51:505-512.
56. Pittler M.H., Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev 2003, 1. CD003383.
57. Witte S., Loew D., Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005, 19(3):183-188.
58. Sarris J., Kavanagh D.J., Byrne G., et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology 2009, 205:399-407.
59. Boerner R.J., Sommer H., Berger W., et al. Kava-kava extract LI 150 is as effective as opipramol and buspirone in generalized anxiety disorder: an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 2003, 10(Suppl 4):38-49.
60. Connor K.M., Payne V., Davidson J.R. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006, 21:249-253.
61. Cloutre D.L. Kava kava: examining new reports of toxicity. Toxicol Lett 2004, 150:85-96.
62. Brown A.C., Onopa J., Holck P., et al. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. Clin Toxicol (Phila) 2007, 45:549-556.
63. Coulter D. Assessment of the risk of hepatotoxicity with kava products 2007, WHO Appointed Committee, World Health Organization, Geneva.
64. Benjamin J., Levine J., Fux M., et al. Double-blind, placebo-controlled, crossover study of inositol treatment for panic disorder. Am J Psychiatry 1995, 152:1084-1086.
65. Palatnick A., Frolov K., Fux M., et al. Double-blind controlled crossover trial of inositol versus fluvoxamine in panic disorder. J Clin Psychopharmacol 2001, 21:335-339.
66. Fux M., Levine J., Aviv A., et al. Inositol treatment of obsessive compulsive disorder. Am J Psychiatry 1996, 153:1219-1221.
67. Fux M., Benjamin J., Belmaker R.H. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind crossover study. Int J Neuropsychopharmacol 1999, 2:193-195.
68. Mori A., Hasegawa K., Murasaki M., et al. Clinical evaluation of passiflamin (passiflora extract) on neurosis - multicenter double blind study in comparison with mexazolam. Clinical Evaluation 1993, 21:383-440.
69. Akhondzadeh S., Naghavi H.R., Vazirian M., et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001, 26:363-367.
70. Miyasaka L.S., Atallah Á.N., Soares B. Passiflora for anxiety disorder. Cochrane Database Syst Rev 2007, 1. CD004518.
71. Ohayon M.M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002, 6(2):97-111.
72. Bonneford A., Tassi P., Roge J., et al. A critical review of techniques aiming at enhancing and sustaining worker's alertness during the night shift. Ind Health 2004, 42(1):1-14.
73. Melamed S., Okenberg A. Excessive daytime sleepiness and risk of occupational injuries in non-shift daytime workers. Sleep 2002, 25(3):315-322.
74. Wilson J.F. Is sleep the new vital sign?. Ann Intern Med 2005, 142(10):877-880.
75. Pearson N.J., Johnson L.L., Nahin R. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 nation health interview survey data. Arch Intern Med 2006, 166(16):1775-1782.
76. Yuan C.S., Mehendale S., Xiao Y., et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 2004, 98:353-358.
77. Miyasaka L.S., Atallah Á.N., Soares B. Valerian for anxiety disorders. Cochrane Database Syst Rev 2006, 4. CD004515.
78. Brent S., Padula A., Moore D., et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med 2006, 119(12):1005-1012.
79. Taibi D.M., Landis C.A., Petry H., et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007, 11:209-230.
80. Buscemi N., Vandermeer B., Hooton N., et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005, 20:1151-1158.
81. Buscemi N., Vandermeer B., Hooton N., et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006, 332:385-393.
82. Buscemi N., Vandermeer B., Pandya R., et al. Melatonin for treatment of sleep disorders. Summary, evidence report/technology assessment No. 108 2004, AHRQ Publication No. 05-E002-1, Agency for Healthcare Research and Quality, Rockville (MD).
83. Herxheimer A., Petrie K.K.J. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002, 2. CD001520.
84. Cheuk D.K.L., Yeung J., Chung K.F., et al. Acupuncture for insomnia. Cochrane Database Syst Rev 2007, 3. CD005472.
85. Winbush N.Y., Gross C.R., Kreitzer M.J. The effects of mindfulness-based stress reduction on sleep disturbance: a systematic review. Explore (NY) 2007, 3(6):585-591.
86. Anon Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000, 105:1158-1170.
87. Wender P.H., Wolf L.E., Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci 2001, 931:1-16.
88. Chan E., Rappaport L.A., Kemper K.J. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr 2003, 24(1):4-8.
89. Arnold L.E., DiSilvestro R.A. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005, 15:619-627.
90. Arnold L.E., Votolato N.A., Kleykamp D., et al. Does hair zinc predict amphetamine improvement of ADD/hyperactivity?. Int J Neurosci 1990, 50:103-107.
91. Bilici M., Yildirim F., Kandil S., et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:181-190.
92. Akhondzadeh S., Mohammadi M.R., Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry 2004, 4:9.
93. Sinn N., Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007, 28:82-91.
94. Clayton E.H., Hanstock T.L., Garg M.L., et al. Long chain omega-3 polyunsaturated fatty acids in the treatment of psychiatric illnesses in children and adolescents. Acta Neuropsychiatrica 2007, 19:92-103.
95. Richardson A.J., Puri B.K. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:233-239.
96. Stevens L., Zhang W., Peck L., et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003, 38:1007-1021.
97. Aman M.G., Mitchell E.A., Turbott S.H. The effects of fatty acid supplementation by efamol on hyperactive children. J Abnorm Child Pyschol 1987, 15:75-90.
98. Voight R, Llorente A, Jensen C, et al. Effect of dietary docosohexaenoic acid supplementation on children with ADHD: preliminary unpublished data. NIH workshop on omega-3 essential fatty acids and psychiatric disorders, September 2-3, 1998.
99. Arnold L.E., Kleykamp D., Votolato N.A., et al. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry 1989, 25:222-228.
100. Hirayama S., Hamazaki T., Terasawa K. Effect of decosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double blind study. Eur J Clin Nutr 2004, 58:467-473.
101. Raz R., Gabis L. Essential fatty acids and attention-deficit hyperactivity disorder: a systematic review. Dev Med Child Neurol 2009, 51:580-592.
102. Shaw K., Turner J., Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002, (1). CD003198.
103. Schmidt P.J., Daly R.C., Bloch M., et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005, 62(2):154-162.
104. Devoe L.D., Castillo R.A., Searle N.S. Maternal dietary substrates and human fetal biophysical activity. The effects of tryptophan and glucose on fetal breathing movements. Am J Obstet Gynecol 1986, 155:135-139.
105. Hibbeln J.R., Davis J.M., Steer C., et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 2007, 369:578-585.
106. Freeman M.P., Davis M., Sinha P., et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008, 110:142-148.
107. The complete German commission E monographs: therapeutic guide to herbal medicines. Trans. S. Klein 1998, 371. American Botanical Council, Boston. M. Blumenthal (Ed.).
108. Wuthrich B., Schmid-Grendelmeyer P., Lundberg M. Anaphylaxis to saffron. Allergy 1997, 52:476-477.
109. Soh N., Walter G. Complementary medicine for psychiatric disorders in children and adolescents. Curr Opin Psychiatry 2008, 21:350-355.
110. Dugoua J.J., Mills E., Perri D., et al. Safety and efficacy of St. John's wort (Hypericum) during pregnancy and lactation. Can J Clin Pharmacol 2006, 13(3):268-276.
111. Smith C.A., Hay P.P.J. Acupuncture for depression. Cochrane Database Syst Rev 2004, 3. CD004046.
112. Stathopoulou G., Pwers M.B., Berry A.C., et al. Exercise interventions for mental health: a quantitative and qualitative review. Clin Psychol Sci Pract 2006, 13:179-193.
113. Mead G.E., Morley W., Campbell P., et al. Exercise for depression. Cochrane Database Syst Rev 2008, 4. CD004366.
114. Van der Watt G., Laugharne J., Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry 2008, 21:37-42.
115. Morgan A.J., Jorm A.F. Self-help interventions for depressive disorders and depressive symptoms: a systematic review. Ann Gen Psychiatry 2008, 7:13.
116. Pilkingon K., Kirkwood G., Rampes H., et al. Homeopathy for depression: a systematic review of the research evidence. Homeopathy 2005, 94(3):153-163.
117. Carrasco M.C., Vallejo J.R., Pardo-de-Santayanna M., et al. Interactions of Valeriana officinalis and Passiflora incarnate L. in a patient treated with lorazepam. Phytother Res 2009, 23(12):1795-1796.
118. Hanus M., Lafon J., Mathieu M. Double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacatha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin 2004, 20(1):63-71.
119. Holst L., Nordeng H., Haavik S. Use of herbal drugs during early pregnancy in relation to maternal characteristics and pregnancy outcome. Pharmacoepidemiol Drug Saf 2008, 17:151-159.
120. Garges H.P., Varia I., Doraiswamy P.M. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998, 280:1566-1567. [letter to the editor].
121. Manzoni G.M., Pagnini F., Castelnuovo G., et al. Relaxation training for anxiety: a ten year systematic review with meta-analysis. BMC Psychiatry 2008, 8:41-53.
122. Pilkington K., Kirkwood G., Rampes H., et al. Homeopathy for anxiety and anxiety disorders: a systematic review of the research. Homeopathy 2006, 95:151-162.
123. Scully D., Kremer J., Meade M.M., et al. Physical exercise and psychological well being: a critical review. Br J Sports Med 1998, 32:111-120.
124. Rucklidge J.J., Johnstone J., Kaplan B.J. Nutrient supplementation approaches in the treatment of ADHD. Expert Rev Neurother 2009, 9(4):461-476.
125. Food and Nutrition Board, Institute of Medicine Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc 2002, National Academy Press, Washington, DC.
126. Arnold L.E. Treatment alternatives for attention-deficit/hyperactivity disorder. Attention-deficit/hyperactivity disorder: state of the science and best practices 2002, Civic Research Institute, Kingston (NJ), p. 1-21. Chapter 6. P.J. Jensen, J. Cooper (Eds.).
127. Loo S.K., Barkley R.A. Clinical utility of EEG in attention deficit hyperactivity disorder. Appl Neuropsychol 2005, 12(2):64-76.
128. Coulter M.K., Dean M.E. Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder. Cochrane Database Syst Rev 2007, 4. CD005648.